GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ)
$67.74 2 (3.0423%)
Analysed GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) News Sources
GE HealthCare to acquire Sofie Biosciences for $945 million
05-10-2026
qz.com
GE HealthCare To Acquire SOFIE Biosciences For $945M — Here’s What GEHC Investors Need To Know
05-10-2026
stocktwits.com
GE HealthCare to acquire Sofie Biosciences for $945M
05-10-2026
medtechdive.com
GE Healthcare to Buy Sofie Biosciences for $945 Million
05-10-2026
yahoo.com
GE HealthCare agrees to acquire SOFIE Biosciences in $945m deal
05-10-2026
medicaldevice-network.com
GE Healthcare's Sofie Deal to Vertically Integrate Radiopharma Portfolio, Needham Says
05-10-2026
yahoo.com
The Bull Case For GE HealthCare (GEHC) Could Change Following Imaging Software Recall And Dividend Hike – Learn Why
06-10-2026
yahoo.com
GE HealthCare to announce third quarter 2026 results on October 28, 2026
07-10-2026
yahoo.com
2 Mid-Cap Stocks to Keep an Eye On and 1 We Question
08-10-2026
yahoo.com
Why GE HealthCare (GEHC) Is Doubling Down on Pharmaceutical Diagnostics?
09-10-2026
yahoo.com
What is the current price of GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ)?
The current price of GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) is $67.74.
GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) absolute price change since previous trading day?
The absolute price change of GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) since the previous trading day is $2.
GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) percentage price change since previous trading day?
The percentage price change of GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) since the previous trading day is 3.0423%.
What is the most recent average sentiment score for GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ)?
The most recent average sentiment score for GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ)?
The most recent sentiment for GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ) is .
SEC-8K** Filing Available For GE HEALTHCARE TECHNOLOGY (GEHC:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.